BHG (replaced AG as diagnostic criteria in latest DKA/HHS guidelines) 0.5 (units/kg/day; recommend starting dose for new start insulin) 50 (average mg/dL drop in BGL per 1 unit rapid acting insulin) LR (fluid choiced for faster resolution of acidosis in DKA) 3.3 (mimimum mEq/L K should be prior to initiated insulin infusion) Awiqli (newest FDA approved insulin) Basal (another term for long acting insulin) 300 (BGL cut off to start adding dextrose to fluids in HHS) Fluids (most important initial treatment in hyperglycemic emergencies) Polydipsia, polyphagia, polyuria (hallmark symptoms of uncontrolled/undiagnosed DM) 600 (BGL level with HHS glucose diagnostic criteria/max MHS glucommander reading) <6.9 (pH cut off for routine administration of sodium bicarb) Euglycemic (Type of DKA that can be an adverse event with use of SGLT2s) Lactic acidosis (possible complication of hallmark DM oral therapy) 320 (Total serum omolarity cut off for HHS) 1 (units/mL; standard concentration of IV insulin infusion) Kussmals (types of respirations associated with DKA) <7.3 (pH criteria for DKA diagnosis) Infection (driver of DKA outside of non compliance and new diagnosis) IV (should only be used for patients with DKA/HHS/Hyperkalemia) 126 (Fasting BGL for DM diagnosis) 6.5 (A1C DM diagnostic criteria) 250 (BGL cut off to start adding dextrose to fluids in DKA) Octerotide (medication that be used in SU/insulin overdose) Cerebral Edema (complication of rapidly decreasing BGL in HHS patients (primarily in the young) 0.1 (units/kg/hr for non glucommander DKA/HHS) 20 (# mEq of K that should be added to each liter with concurrent insulin infusion) SQUID (protocol/trial that supported the addition of SQ insulin in the magangement of mild DKA) BHG (replaced AG as diagnostic criteria in latest DKA/HHS guidelines) 0.5 (units/kg/day; recommend starting dose for new start insulin) 50 (average mg/dL drop in BGL per 1 unit rapid acting insulin) LR (fluid choiced for faster resolution of acidosis in DKA) 3.3 (mimimum mEq/L K should be prior to initiated insulin infusion) Awiqli (newest FDA approved insulin) Basal (another term for long acting insulin) 300 (BGL cut off to start adding dextrose to fluids in HHS) Fluids (most important initial treatment in hyperglycemic emergencies) Polydipsia, polyphagia, polyuria (hallmark symptoms of uncontrolled/undiagnosed DM) 600 (BGL level with HHS glucose diagnostic criteria/max MHS glucommander reading) <6.9 (pH cut off for routine administration of sodium bicarb) Euglycemic (Type of DKA that can be an adverse event with use of SGLT2s) Lactic acidosis (possible complication of hallmark DM oral therapy) 320 (Total serum omolarity cut off for HHS) 1 (units/mL; standard concentration of IV insulin infusion) Kussmals (types of respirations associated with DKA) <7.3 (pH criteria for DKA diagnosis) Infection (driver of DKA outside of non compliance and new diagnosis) IV (should only be used for patients with DKA/HHS/Hyperkalemia) 126 (Fasting BGL for DM diagnosis) 6.5 (A1C DM diagnostic criteria) 250 (BGL cut off to start adding dextrose to fluids in DKA) Octerotide (medication that be used in SU/insulin overdose) Cerebral Edema (complication of rapidly decreasing BGL in HHS patients (primarily in the young) 0.1 (units/kg/hr for non glucommander DKA/HHS) 20 (# mEq of K that should be added to each liter with concurrent insulin infusion) SQUID (protocol/trial that supported the addition of SQ insulin in the magangement of mild DKA)
(Print)
BHG (replaced AG as diagnostic criteria in latest DKA/HHS guidelines)
0.5 (units/kg/day; recommend starting dose for new start insulin)
50 (average mg/dL drop in BGL per 1 unit rapid acting insulin)
LR (fluid choiced for faster resolution of acidosis in DKA)
3.3 (mimimum mEq/L K should be prior to initiated insulin infusion)
Awiqli (newest FDA approved insulin)
Basal (another term for long acting insulin)
300 (BGL cut off to start adding dextrose to fluids in HHS)
Fluids (most important initial treatment in hyperglycemic emergencies)
Polydipsia, polyphagia, polyuria (hallmark symptoms of uncontrolled/undiagnosed DM)
600 (BGL level with HHS glucose diagnostic criteria/max MHS glucommander reading)
<6.9 (pH cut off for routine administration of sodium bicarb)
Euglycemic (Type of DKA that can be an adverse event with use of SGLT2s)
Lactic acidosis (possible complication of hallmark DM oral therapy)
320 (Total serum omolarity cut off for HHS)
1 (units/mL; standard concentration of IV insulin infusion)
Kussmals (types of respirations associated with DKA)
<7.3 (pH criteria for DKA diagnosis)
Infection (driver of DKA outside of non compliance and new diagnosis)
IV (should only be used for patients with DKA/HHS/Hyperkalemia)
126 (Fasting BGL for DM diagnosis)
6.5 (A1C DM diagnostic criteria)
250 (BGL cut off to start adding dextrose to fluids in DKA)
Octerotide (medication that be used in SU/insulin overdose)
Cerebral Edema (complication of rapidly decreasing BGL in HHS patients (primarily in the young)
0.1 (units/kg/hr for non glucommander DKA/HHS)
20 (# mEq of K that should be added to each liter with concurrent insulin infusion)
SQUID (protocol/trial that supported the addition of SQ insulin in the magangement of mild DKA)
